MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
- 1 July 2013
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 12 (7) , 669-676
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Time to first relapse as an endpoint in multiple sclerosis clinical trialsMultiple Sclerosis Journal, 2012
- Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosisMultiple Sclerosis Journal, 2010
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approachAnnals of Neurology, 2009
- MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1bNeurology, 2003
- MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patientsNeurology, 2002
- Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data setsJournal of Neurology, Neurosurgery & Psychiatry, 2001
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993